Neuberger Berman Group
KRTX

Neuberger Berman Group’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Neuberger Berman Group’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-58,503
Closed -$18.5M – 1948
2023
Q4 		$18.5M Buy
58,503
+57,215
+4,442% +$11.1M 0.02% 637
2023
Q3 		$218K Buy
+1,288
New +$242K ﹤0.01% 1671
2023
Q2 		– Sell
-10,235
Closed -$1.86M – 1897
2023
Q1 		$1.86M Buy
10,235
+267
+3% +$51.1K ﹤0.01% 1106
2022
Q4 		$1.96M Buy
9,968
+168
+2% +$36K ﹤0.01% 1073
2022
Q3 		$2.21M Sell
9,800
-22,445
-70% -$4.54M ﹤0.01% 1055
2022
Q2 		$4.08M Sell
32,245
-376
-1% -$43.2K ﹤0.01% 945
2022
Q1 		$4.14M Buy
32,621
+396
+1% +$44.6K ﹤0.01% 1013
2021
Q4 		$4.1M Sell
32,225
-8,940
-22% -$1.16M ﹤0.01% 1027
2021
Q3 		$4.92M Buy
41,165
+5,821
+16% +$672K ﹤0.01% 959
2021
Q2 		$4.02M Buy
+35,344
New +$4.13M ﹤0.01% 1016

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

Neuberger Berman Group's KRTX Position: Q1 2024 in Review

Neuberger Berman Group sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 58,503 shares — an estimated $18.5M sold.

Neuberger Berman Group first reported a position in KRTX in Q2 2021 and held it in 10 quarters. The position peaked at $18.5M in Q4 2023. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Neuberger Berman Group reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Neuberger Berman Group sold 58,503 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $18.5M.
  • Neuberger Berman Group first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2021 and held it in 10 quarters.
  • Neuberger Berman Group's Karuna Therapeutics, Inc. Common Stock position peaked at $18.5M in Q4 2023.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Neuberger Berman Group's 13F filing for Q1 2024, filed 13 May 2024.